Daraxonrasib (Rasonque)
Treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
In 500 patients with previously treated metastatic pancreatic cancer, daraxonrasib vs investigator's-choice chemotherapy gave median overall survival of 13.2 vs 6.6 months in the RAS G12 population (HR 0.40); median PFS 7.3 vs 3.5 months (HR 0.45). Grade ≥3 events 61.8% vs 69.6%. RCT · phase 3 · n = 500 · N Engl J Med · 2026
Orphan